

Wojciech Krzyzanski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2285723/publications.pdf>

Version: 2024-02-01

96
papers

2,127
citations

201674

27
h-index

265206

42
g-index

98
all docs

98
docs citations

98
times ranked

1137
citing authors

#	ARTICLE	IF	CITATIONS
1	Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition. <i>Pharmaceutical Research</i> , 2005, 22, 1589-1596.	3.5	190
2	Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 26, 295-306.	4.0	90
3	Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 23-43.	0.6	78
4	Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 25-47.	1.8	77
5	Basic pharmacodynamic models for agents that alter production of natural cells. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 467-489.	1.8	76
6	Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Heparin in Cynomolgus Monkeys. <i>AAPS Journal</i> , 2010, 12, 646-657.	4.4	74
7	Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects. <i>AAPS Journal</i> , 2010, 12, 729-740.	4.4	68
8	Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 1297-1306.	2.5	64
9	Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 849-868.	1.8	63
10	Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1997, 25, 107-123.	0.6	55
11	Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition. <i>AAPS Journal</i> , 2015, 17, 389-399.	4.4	47
12	Integrated Functions for Four Basic Models of Indirect Pharmacodynamic Response. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 67-72.	3.3	46
13	Population Modeling of Filgrastim PK/PD in Healthy Adults Following Intravenous and Subcutaneous Administrations. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 101S-112S.	2.0	45
14	Population Cell Life Span Models for Effects of Drugs Following Indirect Mechanisms of Action. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 767-793.	1.8	41
15	Pharmacodynamic model for chemotherapy-induced anemia in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 123-133.	2.3	41
16	Pharmacodynamic Analysis of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2008, 47, 399-415.	3.5	41
17	ALGORITHM FOR APPLICATION OF FOURIER ANALYSIS FOR BIORHYTHMIC BASELINES OF PHARMACODYNAMIC INDIRECT RESPONSE MODELS. <i>Chronobiology International</i> , 2000, 17, 77-93.	2.0	40
18	Pharmacokinetic model of target-mediated disposition of thrombopoietin. <i>AAPS PharmSci</i> , 2004, 6, 86-93.	1.3	40

#	ARTICLE	IF	CITATIONS
19	Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 179-204.	1.8	38
20	Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of Lifespans. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 125-166.	1.8	37
21	Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimeticbodyâ„¢ Construct CNTO 528 in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2009, 48, 601-613.	3.5	35
22	Population Pharmacokinetic and Pharmacodynamic Modelâ€”Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1624-1644.	2.0	34
23	Multiple-pool cell lifespan model of hematologic effects of anticancer agents. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 311-337.	1.8	32
24	Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 543-560.	1.8	31
25	Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 291-318.	1.8	30
26	An Assessment of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Lifespan Distribution in Healthy Subjects. <i>Pharmaceutical Research</i> , 2007, 24, 758-772.	3.5	29
27	Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2008, 35, 349-377.	1.8	29
28	Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 637-645.	3.0	29
29	Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals. <i>Pharmaceutical Research</i> , 2013, 30, 655-669.	3.5	27
30	Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 385-408.	0.6	26
31	Partial derivativeâ€”Based sensitivity analysis of models describing target-mediated drug disposition. <i>AAPS Journal</i> , 2007, 9, E181-E189.	4.4	26
32	Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 43-52.	2.0	26
33	FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition. <i>Pharmaceutical Research</i> , 2016, 33, 1833-1849.	3.5	26
34	Flow cytometric assessment of homeostatic aging of reticulocytes in rats. <i>Experimental Hematology</i> , 2008, 36, 119-127.	0.4	25
35	Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 199-219.	1.8	25
36	Pharmacodynamic Modeling of Lansoprazole Using an Indirect Irreversible Response Model. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 251-258.	2.0	24

#	ARTICLE	IF	CITATIONS
37	Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations. <i>Clinical Pharmacokinetics</i> , 2009, 48, 817-826.	3.5	23
38	Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition. , 2001, 28, 57-78.		21
39	Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 897-910.	2.5	20
40	A Signal Transduction Pharmacodynamic Model of the Kinetics of the Parasympathomimetic Activity of Low-Dose Scopolamine and Atropine in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2500-2510.	3.3	19
41	Lifespan based indirect response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 109-123.	1.8	16
42	Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1063-1083.	3.5	16
43	Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2009, 75A, 584-592.	1.5	15
44	Mathematical Assessment of Properties of Precursor-Dependent Indirect Pharmacodynamic Response Models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 683-717.	1.8	13
45	Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2007, 71A, 460-467.	1.5	13
46	Reticulocyte-based estimation of red blood cell lifespan. <i>Experimental Hematology</i> , 2013, 41, 817-822.	0.4	13
47	Solving delay differential equations in S-ADAPT by method of steps. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 111, 715-734.	4.7	12
48	Assessment of Dosing Impact on Intra-Individual Variability in Estimation of Parameters for Basic Indirect Response Models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 635-655.	1.8	11
49	Characterization of pharmacodynamic recession slopes for direct and indirect response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 409-436.	0.6	10
50	Pharmacodynamic Modeling of Thrombopoietin, Platelet, and Megakaryocyte Dynamics in Patients with Acute Myeloid Leukemia Undergoing Dose Intensive Chemotherapy. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 501-511.	2.0	10
51	Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 298-315.	1.9	10
52	Indirect pharmacodynamic models for responses with circadian removal. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 89-101.	1.8	10
53	Use of a Local Sensitivity Analysis to Inform Study Design Based on a Mechanistic Toxicokinetic Model for β -Hydroxybutyric Acid. <i>AAPS Journal</i> , 2011, 13, 240-254.	4.4	9
54	Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 141-146.	1.8	9

#	ARTICLE	IF	CITATIONS
55	Erythropoietin-Induced Erythroid Precursor Pool Depletion Causes Erythropoietin Hyporesponsiveness. <i>Pharmaceutical Research</i> , 2013, 30, 1026-1036.	3.5	9
56	Simplification of Complex Physiologically Based Pharmacokinetic Models of Monoclonal Antibodies. <i>AAPS Journal</i> , 2014, 16, 810-842.	4.4	9
57	Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 261-272.	1.8	9
58	Application of moment analysis to the sigmoid effect model for drug administered intravenously. , 1997, 14, 949-952.		8
59	D-optimal designs for parameter estimation for indirect pharmacodynamic response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 523-539.	1.8	8
60	Pharmacodynamic models of age-structured cell populations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 573-589.	1.8	8
61	Ordinary differential equation approximation of gamma distributed delay model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 53-63.	1.8	8
62	Mechanism of ethanol enhancement of apoptosis and caspase activation in serum-deprived PC12 cells. <i>Life Sciences</i> , 2007, 81, 756-764.	4.3	7
63	Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 1-15.	1.9	7
64	The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats. <i>Biopharmaceutics and Drug Disposition</i> , 2014, 35, 330-340.	1.9	7
65	Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys. <i>AAPS Journal</i> , 2016, 18, 713-727.	4.4	7
66	Population Model of Serum Creatinine as Time-Dependent Covariate in Neonates. <i>AAPS Journal</i> , 2021, 23, 86.	4.4	7
67	Asymptotics of the total net direct pharmacological effect for large drug doses. <i>Journal of Mathematical Biology</i> , 2000, 41, 477-492.	1.9	6
68	Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats. <i>Frontiers in Pharmacology</i> , 2018, 9, 316.	3.5	6
69	Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B. <i>PLoS ONE</i> , 2017, 12, e0171834.	2.5	5
70	Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 411-438.	1.8	5
71	Lifespan Based Pharmacokinetic-Pharmacodynamic Model of Tumor Growth Inhibition by Anticancer Therapeutics. <i>PLoS ONE</i> , 2014, 9, e109747.	2.5	5
72	Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1438-1454.	3.3	4

#	ARTICLE	IF	CITATIONS
73	Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 709-720.	1.8	4
74	A cell-level model of pharmacodynamics-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 513-527.	1.8	4
75	Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens. AAPS Journal, 2020, 22, 30.	4.4	4
76	Delay differential equations based models in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 763-802.	1.8	4
77	Fate Determination Role of Erythropoietin and Romiplostim in the Lineage Commitment of Hematopoietic Progenitors. Journal of Pharmacology and Experimental Therapeutics, 2022, 382, 31-43.	2.5	4
78	Note: caution in use of empirical equations for pharmacodynamic indirect response models. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 735-741.	0.6	3
79	vRNA structured population model for Hepatitis C Virus dynamics. Journal of Theoretical Biology, 2015, 378, 1-11.	1.7	3
80	Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates. AAPS Journal, 2019, 21, 68.	4.4	3
81	A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 687-710.	1.8	3
82	Analysis of a model of membrane potential for a skin receptor. Mathematical Biosciences, 1999, 158, 1-45.	1.9	2
83	NEURONAL INTEGRATIVE ANALYSIS OF THE "DUMBBELL" MODEL FOR PASSIVE NEURONS. Journal of Integrative Neuroscience, 2002, 01, 217-239.	1.7	2
84	Age-structured population model of cell survival. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 305-316.	1.8	2
85	Evaluation of performance of distributed delay model for chemotherapy-induced myelosuppression. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 329-337.	1.8	2
86	Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. Journal of Clinical Pharmacology, 2019, 59, 418-426.	2.0	2
87	Direct, Indirect, and Signal Transduction Response Modeling. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 177-209.	0.6	1
88	Application of Reticulocyte-Based Estimation of Red Blood Cell Lifespan in Anemia Management of End-Stage Renal Disease Patients. AAPS Journal, 2020, 22, 40.	4.4	1
89	Modelling the geometric features and investigating electrical properties of dendrites in a fish thalamic neuron. Mathematical Medicine and Biology, 2007, 24, 271-286.	1.2	0
90	Population Pharmacodynamic Modeling of Epoetin Alfa in End-Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 596-605.	2.5	0

#	ARTICLE	IF	CITATIONS
91	Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 826-838.	2.5	0
92	Comparison of Homeostatic Reticulocyte Aging between Normal and Belgrade Rats Using Flow Cytometry.. Blood, 2007, 110, 2682-2682.	1.4	0
93	Pharmacokinetics and Pharamcodynamics of Recombinant Human Thrombopoietin Following Single Injection in Rats. Blood, 2008, 112, 5400-5400.	1.4	0
94	Exposure to Recombinant Human Erythropoietin Increases Survival of Red Blood Cells in Wistar Rats.. Blood, 2009, 114, 5087-5087.	1.4	0
95	A Mechanism Based Pharmacokinetic/Pharmacodynamic Model of the Effect of a Prolyl Hydroxylase Inhibitor on Erythropoietic Response In Mice. Blood, 2010, 116, 4769-4769.	1.4	0
96	Dynamics of Erythroferrone Response to Erythropoietin in Rats. Frontiers in Pharmacology, 2022, 13, 876573.	3.5	0